Hamaguchi Rika, Takemori Kumiko, Inoue Takao, Masuno Kouichi, Ito Hiroyuki
Department of Pathology, Kinki University School of Medicine, Osaka, Japan.
Clin Exp Pharmacol Physiol. 2008 Oct;35(10):1151-5. doi: 10.1111/j.1440-1681.2008.04973.x. Epub 2008 Jun 1.
The aim of the present study was to investigate the effects of short-term treatment with an AT(1) receptor blocker (ARB) on amelioration of hypertensive end-organ damage in stroke-prone spontaneously hypertensive rats (SHRSP). Male SHRSP were divided into two groups: (i) an ARB-treated group; and (ii) a control group. Candesartan (1 mg/kg per day) was administered orally from 6 to 11 weeks of age. At 20 weeks of age, plasma renin activity (PRA), angiotensin II concentrations, angiotensin-converting enzyme (ACE) activity and hydroperoxide content were measured. Expression of intercellular adhesion molecule (ICAM)-1, renin, AT(1) and AT(2) receptors was investigated by reverse transcription-polymerase chain reaction. Blood pressure in the ARB group was slightly lower at 7, 8, 11, 13-15 and 18 weeks of age, but no significant difference in blood pressure was found between the ARB and control groups at 20 weeks of age. All rats in the control group had cerebral oedema, whereas no lesions were found in the ARB group. In the ARB group, PRA, AII and hydroperoxide content were lower than in the control group. In the ARB-treated group, lower ICAM-1 expression was found in the cerebral cortex and slightly, albeit not significantly, lower expression of renin was found in the kidney. In contrast, AT(1) receptor expression in the cerebrum and kidney was higher in the ARB group compared with the control group. These results indicate that short-term treatment of SHRSP with ARB at a young age is effective in preventing cerebral oedema after maturation. Such beneficial effects of ARB may be due, in part, to decreased blood pressure and is likely mainly due to inhibition of total circulating and local renin-angiotensin systems.
本研究的目的是探讨用血管紧张素Ⅱ1型受体阻滞剂(ARB)短期治疗对易卒中型自发性高血压大鼠(SHRSP)高血压靶器官损害改善情况的影响。雄性SHRSP大鼠分为两组:(i)ARB治疗组;(ii)对照组。从6周龄至11周龄每天口服坎地沙坦(1毫克/千克)。在20周龄时,测量血浆肾素活性(PRA)、血管紧张素Ⅱ浓度、血管紧张素转换酶(ACE)活性和过氧化氢含量。通过逆转录-聚合酶链反应研究细胞间黏附分子(ICAM)-1、肾素、血管紧张素Ⅱ1型和2型受体的表达。ARB组在7、8、11、13 - 15和18周龄时血压略低,但在20周龄时ARB组和对照组之间血压无显著差异。对照组所有大鼠均有脑水肿,而ARB组未发现病变。在ARB组中,PRA、血管紧张素Ⅱ和过氧化氢含量低于对照组。在ARB治疗组中,大脑皮质中ICAM-1表达较低,肾脏中肾素表达略低,尽管不显著。相反,与对照组相比,ARB组大脑和肾脏中血管紧张素Ⅱ1型受体表达较高。这些结果表明,幼年时用ARB对SHRSP进行短期治疗可有效预防成熟后脑水肿。ARB的这种有益作用可能部分归因于血压降低,并且可能主要是由于抑制了全身循环和局部肾素-血管紧张素系统。